RESUMO
Glioblastomas (GBMs), the most frequent and aggressive human primary brain tumours, have altered cell metabolism, and one of the strongest indicators of malignancy is an increase in choline compounds. Choline is also a selective agonist of some neuronal nicotinic acetylcholine receptor (nAChR) subtypes. As little is known concerning the expression of nAChR in glioblastoma cells, we analysed in U87MG human grade-IV astrocytoma cell line and GBM5 temozolomide-resistant glioblastoma cells selected from a cancer stem cell-enriched culture, molecularly, pharmacologically and functionally which nAChR subtypes are expressed and,whether choline and nicotine can affect GBM cell proliferation. We found that U87MG and GBM5 cells express similar nAChR subtypes, and choline and nicotine increase their proliferation rate and activate the anti-apoptotic AKT and pro-proliferative ERK pathways. These effects are blocked by the presence of non-cell-permeable peptide antagonists selective for α7- and α9-containing nicotinic receptors. siRNA-mediated silencing of α7 or α9 subunit expression also selectively prevents the effects of nicotine and choline on GBM cell proliferation. Our findings indicate that nicotine and choline activate the signalling pathways involved in the proliferation of GBM cells, and that these effects are mediated by α7 and α9-containing nAChRs. This suggests that these nicotinic receptors may contribute to the aggressive behaviour of this tumor and may indicate new therapeutic strategies against high-grade human brain tumours.
Assuntos
Neoplasias Encefálicas/metabolismo , Colina/farmacologia , Glioblastoma/metabolismo , Nicotina/farmacologia , Receptores Nicotínicos/metabolismo , Receptor Nicotínico de Acetilcolina alfa7/metabolismo , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Humanos , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Proteínas Proto-Oncogênicas c-akt/metabolismo , RNA Interferente Pequeno/genética , Receptores Nicotínicos/genética , Receptor Nicotínico de Acetilcolina alfa7/genéticaRESUMO
Tobacco addiction is a complex form of dependence process that leads high relapse rates in people seeking to stop smoking. Nicotine elicits its primary effects on neuronal nicotinic cholinergic receptors (nAChRs), alters brain reward systems, and induces long-term changes during chronic nicotine use and withdrawal. We analysed the effects of chronic nicotine treatment and withdrawal on the mesocorticolimbic pathway (a brain reward circuit in which addictive drugs induce widespread adaptations) by analysing the expression of nAChRs in the midbrain, striatum and prefrontal cortex (PFC) of mice receiving intravenous infusions of nicotine (4mg/kg/h) or saline (control) for 14 days and mice sacrified two hours, and one, four and 14 days after treatment withdrawal. We biochemically fractionated whole tissue homogenates in order to obtain crude synaptosomal membranes. Western blotting analyses of these membrane fractions, ligand binding and immunoprecipitation studies, showed that chronic nicotine up-regulates heteromeric ß2* nAChRs in all three mesocorticolimbic areas, and that these receptors are rapidly removed from synapses upon the cessation of nicotine treatment. The extent of nicotine-induced nAChR up-regulation, and the time course of its reversal were comparable in all three areas. We also analysed the expression of glutamate receptor subunits (GluRs) and scaffold proteins, and found that it was altered in an area-specific manner during nicotine exposure and withdrawal. As the functional properties of GluRs are determined by their subunit composition, the observed changes in subunit expression may indicate alterations in the excitability of mesocorticolimbic circuitry, and this may underlie the long-term biochemical and behavioural effects of nicotine dependence.
Assuntos
Encéfalo/metabolismo , Nicotina/farmacologia , Receptores de Glutamato/metabolismo , Receptores Nicotínicos/metabolismo , Tabagismo/metabolismo , Animais , Masculino , Camundongos Endogâmicos C57BL , Síndrome de Abstinência a Substâncias/metabolismoRESUMO
A series of 3-nitrophenyl and 3-hydroxyphenyl ethers of (S)-N-methylprolinol bearing bulky and lipophilic substituents at phenyl C5 were tested for affinity at α4ß2 and α3ß4 nAChRs. The two phenyl ethers 5-substituted with 6-hydroxy-1-hexynyl showed high α4ß2 affinity and significantly increased α4ß2/α3ß4 selectivity compared to the respective unsubstituted parent compounds. Within the two series of novel phenyl ethers, we observed parallel shifts in affinity and, furthermore, the increase in α4ß2/α3ß4 selectivity resulting from the hydroxyalkynyl substitution parallels that reported for the same modification at the 3-pyridyl ether of (S)-N-methylprolinol (A-84543), a well-known potent α4ß2 agonist. On the basis of these results, our nitrophenyl and hydroxyphenyl prolinol ethers can be considered bioisosteres of the pyridyl ether A-84543 and lead compounds candidable to analogous optimization processes.
Assuntos
Agonistas Nicotínicos/química , Agonistas Nicotínicos/farmacologia , Pirrolidinas/química , Pirrolidinas/farmacologia , Receptores Nicotínicos/metabolismo , Animais , Humanos , Ligantes , Éteres Fenílicos/química , Éteres Fenílicos/farmacologia , Piridinas/química , Piridinas/farmacologia , Ratos , Relação Estrutura-AtividadeRESUMO
Changes in the expression of α7 nicotinic acetylcholine receptors (α7 nAChRs) in the human brain are widely assumed to be associated with neurological and neurooncological processes. Investigation of these receptors in vivo depends on the availability of imaging agents such as radioactively labelled ligands applicable in positron emission tomography (PET). We report on a series of new ligands for α7 nAChRs designed by the combination of dibenzothiophene dioxide as a novel hydrogen bond acceptor functionality with diazabicyclononane as an established cationic center. To assess the structure-activity relationship (SAR) of this new basic structure, we further modified the cationic center systematically by introduction of three different piperazine-based scaffolds. Based on in vitro binding affinity and selectivity, assessed by radioligand displacement studies at different rat and human nAChR subtypes and at the structurally related human 5-HT3 receptor, we selected the compound 7-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-2-fluorodibenzo-[b,d]thiophene 5,5-dioxide (10a) for radiolabeling and further evaluation in vivo. Radiosynthesis of [18F]10a was optimized and transferred to an automated module. Dynamic PET imaging studies with [18F]10a in piglets and a monkey demonstrated high uptake of radioactivity in the brain, followed by washout and target-region specific accumulation under baseline conditions. Kinetic analysis of [18F]10a in pig was performed using a two-tissue compartment model with arterial-derived input function. Our initial evaluation revealed that the dibenzothiophene-based PET radioligand [18F]10a ([18F]DBT-10) has high potential to provide clinically relevant information about the expression and availability of α7 nAChR in the brain.
Assuntos
Radioisótopos de Flúor/farmacocinética , Compostos Radiofarmacêuticos/farmacocinética , Receptores 5-HT3 de Serotonina/metabolismo , Tiofenos/farmacocinética , Receptor Nicotínico de Acetilcolina alfa7/metabolismo , Animais , Compostos Aza/química , Encéfalo/metabolismo , Mapeamento Encefálico , Radioisótopos de Flúor/metabolismo , Haplorrinos , Humanos , Ligação de Hidrogênio , Cinética , Ligantes , Óxidos , Piperazinas/química , Tomografia por Emissão de Pósitrons , Ligação Proteica , Compostos Radiofarmacêuticos/síntese química , Compostos Radiofarmacêuticos/metabolismo , Ratos , Relação Estrutura-Atividade , Suínos , Tiofenos/síntese química , Tiofenos/metabolismo , Distribuição TecidualRESUMO
A series of acetylcholine carbamoyl analogues, cyclised at the carbamate moiety or at the cationic head or at both, were tested for binding affinity at muscarinic and neuronal nicotinic receptors (nAChRs). While no muscarinic affinity was found, submicromolar Ki values, similar to that of carbachol, were measured at α4ß2 nAChRs for the enantiomers of 5-dimethylaminomethyl- and 5-trimethylammoniomethyl-2-oxazolidinone, 2 and 2a, and for (S)-N-methylprolinol carbamate (S)-3. Methylation of oxazolidinone nitrogen of 2 and 2a and of N-methylprolinol nitrogen of (S)-3 and, even more, hybridization of cyclic carbamate substructure (oxazolidinone) with cyclic cationic head (N-methylpyrrolidine) markedly lower the nicotinic affinity. Docking results were consistent with SAR analysis highlighting the interaction capabilities of (R)-2a and (S)-3 and the negative effect of intracyclic nitrogen methylation and of double cyclisation.
Assuntos
Acetilcolina/análogos & derivados , Acetilcolina/síntese química , Carbamatos/síntese química , Acetilcolina/química , Animais , Sítios de Ligação , Células CHO , Carbacol/análogos & derivados , Carbacol/síntese química , Carbacol/química , Carbamatos/química , Cricetulus , Desenho de Fármacos , Humanos , Ligantes , Modelos Moleculares , Relação Estrutura-AtividadeRESUMO
(+)-Laburnamine (1), a rare alkaloid extracted from Laburnum anagyroides seeds (â¼4 mg from 1 kg), was shown to bind with high affinity (Ki, 293 nM) to the α4ß2 nicotinic receptor subtype, which is, respectively, 126 and 136 times higher than to the α3ß4 (Ki 37 µM) and α7 subtypes (Ki 40 µM). When its ability to release [(3)H]-dopamine from striatal slices was tested in a functional assay, compound 1 behaved as a partial agonist with an EC50 of 5.8 µM and an Emax that was 43% that of nicotine. When incubated with nicotine in the same assay, 1 prevented a maximal effect from being reached.
Assuntos
Alcaloides/farmacologia , Receptores Nicotínicos/efeitos dos fármacos , Alcaloides/química , Alcaloides/isolamento & purificação , Animais , Ligação Competitiva , Corpo Estriado/metabolismo , Dopamina/metabolismo , Relação Dose-Resposta a Droga , Humanos , Itália , Ligantes , Neostriado/metabolismo , Nicotina/metabolismo , Piridinas/metabolismo , Ratos , Ratos Sprague-Dawley , Sementes/química , EstereoisomerismoRESUMO
BACKGROUND AND PURPOSE: Genomic analysis has shown many variants in both CHRNA4 and CHRNB2, genes which encode the α4 and ß2 subunits of nicotinic ACh receptors (nAChR) respectively. Some variants influence receptor expression, raising the possibility that CHRNA4 variants may affect response to tobacco use in humans. Chronic exposure to nicotine increases expression of nAChRs, particularly α4ß2-nAChRs, in humans and laboratory animals. Here, we have evaluated whether the initial level of receptor expression affects the increase in expression. EXPERIMENTAL APPROACH: Mice differing in expression of α4 and/or ß2 nAChR subunits were chronically treated with saline, 0.25, 1.0 or 4.0 mg·kg-1 ·h-1 nicotine. Brain preparations were analysed autoradiographically by [125 I]-epibatidine binding, immunoprecipitation and Western blotting. KEY RESULTS: Immunochemical studies confirmed that most of the [3 H]-epibatidine binding corresponds to α4ß2*-nAChR and that increases in binding correspond to increases in α4 and ß2 proteins. Consistent with previous reports, the dose-dependent increase in nAChR in wild-type mice following chronic nicotine treatment, measured with any of the methods, reached a maximum. Although receptor expression was reduced by approximately 50% in ß2+- mice, the pattern of response to chronic treatment resembled that of wild-type mice. In contrast, both α4+- and α4+- /ß2+- exhibited relatively greater up-regulation. Consistent with previous reports, α4ß2α5-nAChR did not increase in response to nicotine. CONCLUSIONS AND IMPLICATIONS: These results indicate that mice with reduced expression of the α4 nAChR subunit have a more robust response to chronic nicotine than mice with normal expression of this subunit. LINKED ARTICLES: This article is part of a themed section on Nicotinic Acetylcholine Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.11/issuetoc.
Assuntos
Nicotina/farmacologia , Receptores Nicotínicos/metabolismo , Regulação para Cima/efeitos dos fármacos , Animais , Relação Dose-Resposta a Droga , Feminino , Injeções Intraperitoneais , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Nicotina/administração & dosagem , Receptores Nicotínicos/deficiência , Receptores Nicotínicos/genética , Relação Estrutura-AtividadeRESUMO
BACKGROUND AND PURPOSE: Tobacco smoke contains many classes of carcinogens and although nicotine is unable to initiate tumourigenesis in humans and rodents, it promotes tumour growth and metastasis in lung tumours by acting on neuronal nicotinic ACh receptors (nAChRs). The aim of this study was to identify molecularly, biochemically and pharmacologically which nAChR subtypes are expressed and functionally activated by nicotine in lung cancer cell lines. EXPERIMENTAL APPROACH: We used A549 and H1975 adenocarcinoma cell lines derived from lung tumours to test the in vitro effects of nicotine, and nAChR subtype-specific peptides and compounds. KEY RESULTS: The two adenocarcinoma cell lines express distinctive nAChR subtypes, and this affects their nicotine-induced proliferation. In A549 cells, nAChRs containing the α7 or α9 subunits not only regulate nicotine-induced cell proliferation but also the activation of the Akt and ERK pathways. Blocking these nAChRs by means of subtype-specific peptides, or silencing their expression by means of subunit-specific siRNAs, abolishes nicotine-induced proliferation and signalling. Moreover, we found that the α7 antagonist MG624 also acts on α9-α10 nAChRs, blocks the effects of nicotine on A549 cells and has dose-dependent cytotoxic activity. CONCLUSIONS AND IMPLICATIONS: These results highlight the pathophysiological role of α7- and α9-containing receptors in promoting non-small cell lung carcinoma cell growth and intracellular signalling and provide a framework for the development of new drugs that specifically target the receptors expressed in lung tumours. LINKED ARTICLES: This article is part of a themed section on Nicotinic Acetylcholine Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.11/issuetoc.
Assuntos
Adenocarcinoma/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Nicotina/farmacologia , Receptores Nicotínicos/metabolismo , Receptor Nicotínico de Acetilcolina alfa7/antagonistas & inibidores , Células A549 , Adenocarcinoma/metabolismo , Adenocarcinoma/patologia , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Relação Dose-Resposta a Droga , Humanos , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patologia , Compostos de Amônio Quaternário/farmacologia , Estilbenos/farmacologia , Relação Estrutura-Atividade , Receptor Nicotínico de Acetilcolina alfa7/metabolismoRESUMO
The cholinergic pathways in the central nervous system (CNS) of animals and humans are important for cognitive and behavioural functions. Until a few years ago, it was thought that the key molecules transducing the cholinergic message were the metabotropic muscarinic receptors, but it is now known that ionotropic neuronal nicotinic receptors (nAChRs) are also involved. Based on recent studies, we prepared a small library of novel 3-substituted-3,6-diazabicyclo [3.1.1]heptanes, whose binding activity and functionality have been assayed. Among the synthesized compounds, the 3-(anilino)pyridine series resulted in the most interesting compounds with α4ß2Ki values ranging from 0.0225â¯nM (12g) to 2.06â¯nM (12o).
Assuntos
Compostos de Anilina/farmacologia , Compostos Bicíclicos com Pontes/farmacologia , Receptores Nicotínicos/metabolismo , Compostos de Anilina/química , Animais , Compostos Bicíclicos com Pontes/química , Linhagem Celular , Relação Dose-Resposta a Droga , Humanos , Ligantes , Estrutura Molecular , Ratos , Relação Estrutura-AtividadeRESUMO
Adenocarcinoma and glioblastoma cell lines express α7- and α9α10-containing nicotinic acetylcholine receptors (nAChRs), whose activation promotes tumor cell growth. On these cells, the triethylammoniumethyl ether of 4-stilbenol MG624, a known selective antagonist of α7 and α9α10 nAChRs, has antiproliferative activity. The structural analogy of MG624 with the mitocan RDM-4'BTPI, triphenylphosphoniumbutyl ether of pterostilbene, suggested us that molecular hybridization among their three substructures (stilbenoxy residue, alkylene linker, and terminal onium) and elongation of the alkylene linker might result in novel antitumor agents with higher potency and selectivity. We found that lengthening the ethylene bridge in the triethylammonium derivatives results in more potent and selective toxicity toward adenocarcinoma and glioblastoma cells, which was paralleled by increased α7 and α9α10 nAChR antagonism and improved ability of reducing mitochondrial ATP production. Elongation of the alkylene linker was advantageous also for the triphenylphosphonium derivatives resulting in a generalized enhancement of antitumor activity, associated with increased mitotoxicity.
Assuntos
Glioblastoma/patologia , Espécies Reativas de Oxigênio/química , Receptores Nicotínicos/metabolismo , Estilbenos/química , Estilbenos/farmacologia , Receptor Nicotínico de Acetilcolina alfa7/antagonistas & inibidores , Antineoplásicos/química , Antineoplásicos/farmacologia , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , HumanosRESUMO
Each of the four aromatic -CH= of (S,R)-2-pyrrolidinyl-1,4-benzodioxane [(S,R)-6] and of its epimer at the dioxane stereocenter (S,S)-6, previously reported as α4ß2 nAChR ligands, was replaced with nitrogen. The resulting four diastereoisomeric pairs of pyrrolidinyl-pyridodioxanes were studied for the nicotinic affinity and activity at α4ß2, α3ß4 and α7 nAChR subtypes and compared to their common carbaisostere. It turned out that such isosteric substitutions are highly detrimental, but with the important exception of the S,R stereoisomer of the pyrrolidinyl-pyridodioxane with the pyridine nitrogen adjacent to the dioxane and seven atoms distant from the pyrrolidine nitrogen. Indeed, this stereo/regioisomer not only maintained the α4ß2 affinity of [(S,R)-6], but also greatly improved in selectivity over the α3ß4 and α7 subtypes and, most importantly, exhibited a highly selective α4ß2 partial agonism. The finding that [(S,R)-6] is, instead, an unselective α4ß2 antagonist indicates that the benzodioxane substructure confers affinity for the α4ß2 nAChR binding site, but activation of this receptor subtype needs benzodioxane functionalization under strict steric requirements, such as the previously reported 7-OH substitution or the present isosteric modification.
Assuntos
Dioxanos/química , Dioxanos/farmacologia , Agonistas Nicotínicos/química , Agonistas Nicotínicos/farmacologia , Pirrolidinas/química , Pirrolidinas/farmacologia , Receptores Nicotínicos/metabolismo , Derivados de Benzeno/química , Derivados de Benzeno/farmacologia , Desenho de Fármacos , Células HEK293 , Humanos , Relação Estrutura-AtividadeRESUMO
Lung cancer is the leading cause of cancer-related deaths worldwide. Smoking accounts for approximately 70% of the cases of non- small cell lung cancer (NSCLC) and 90% of the cases of small-cell lung cancer (SCLC), although some patients develop lung cancer without a history of smoking. Nicotine is the most active addictive component of tobacco smoke. It does not initiate tumorigenesis in humans and rodents, but it alters the pathophysiology of lung cells by inducing the secretion of growth factors, neurotransmitters and cytokines, and promotes tumour growth and metastases by inducing cell cycle progression, migration, invasion, angiogenesis and the evasion of apoptosis. Most of these effects are a result of nicotine binding and activation of cell-surface neuronal nicotinic acetylcholine receptors (nAChRs) and downstream intracellular signalling cascades, and many are blocked by nAChR subtype-selective antagonists. Recent genome-wide association studies have revealed single nucleotide polymorphisms of nAChR subunits that influence nicotine dependence and lung cancer. This review describes the molecular basis of nAChR structural and functional diversity in normal and cancer lung cells, and the genetic alterations facilitating smoking-induced lung cancers. It also summarises current knowledge concerning the intracellular pathways activated by nicotine and other compounds present in tobacco smoke.
Assuntos
Antineoplásicos/farmacologia , Agonistas Colinérgicos/farmacologia , Neoplasias Pulmonares/tratamento farmacológico , Receptores Nicotínicos/metabolismo , Proliferação de Células/efeitos dos fármacos , Humanos , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patologia , Polimorfismo de Nucleotídeo Único/genética , Receptores Nicotínicos/genéticaRESUMO
We report the design, synthesis and pharmacological screening of a group of analogues of anabaseine 2, a naturally occurring unselective nicotinic agonist. The novel nAChR ligands 5-15 were planned following a molecular modeling analysis which suggested the replacement of the pyridine ring of 2 with a 3-substituted benzene ring as a means to gain selectivity for the α3ß4 nAChR subtype. Overall, from binding experiments, the synthesized compounds showed high values of α3ß4 affinity and α3ß4 vs α4ß2 selectivity, although they poorly discriminated the homomeric α7 subtype. The three analogues 6, 12 and 13 were also evaluated in electrophysiological assays, and 12 [6-(3-iodophenyl)-2,3,4,5-tetrahydropyridine] emerged as a rather interesting nicotinic ligand. Indeed, in addition to a noteworthy affinity (Ki = 4.7 nM) for the α3ß4 subtype and to an excellent α3ß4 vs α4ß2 subtype selectivity (806-fold), compound 12 selectively activated the α3ß4 nAChR (EC50 = 7.4 µM) while eliciting a negligible response at the α7 subtype and no effect at the α4ß2 subtype.
Assuntos
Anabasina/análogos & derivados , Piridinas/farmacologia , Receptores Nicotínicos/metabolismo , Anabasina/síntese química , Anabasina/química , Anabasina/farmacologia , Sítios de Ligação/efeitos dos fármacos , Linhagem Celular , Relação Dose-Resposta a Droga , Humanos , Modelos Moleculares , Estrutura Molecular , Piridinas/síntese química , Piridinas/química , Relação Estrutura-AtividadeRESUMO
Nicotinic acetylcholine receptors (nAChRs) are a critical component of the brain's cholinergic neurotransmission system that modulates important physiological processes and whose dysfunction has been observed in patients with neurodegenerative diseases and mental illness. nAChRs are a heterogeneous family of receptor subtypes consisting of pentameric combinations of α and ß subunits, and are widely expressed throughout the central and peripheral nervous system. nAChR subtypesnAChR subtypes share a common basic structure but their biophysical and pharmacological properties depend on their subunit compositionSubunit composition , which is therefore central to understanding receptor function in the nervous system and discovering new subtype-selective drugs. We briefly review some recent findings concerning the structure and function of nAChRs, particularly the native subtypes.
Assuntos
Receptores Nicotínicos , Animais , Humanos , Receptores Nicotínicos/classificação , Receptores Nicotínicos/metabolismo , Receptores Nicotínicos/fisiologiaRESUMO
Nicotinic acetylcholine receptors (nAChRs) play an important role in many central nervous system disorders such as Alzheimer's and Parkinson's diseases, schizophrenia, and mood disorders. The α(4)ß(2) subtype has emerged as an important target for the early diagnosis and amelioration of Alzheimer's disease symptoms. Herein we report a new class of α(4)ß(2) receptor ligands characterized by a basic pyrrolidine nucleus, the basicity of which was properly decreased through the insertion of a fluorine atom at the 3-position, and a pyridine ring carrying at the 3-position substituents known to positively affect affinity and selectivity toward the α(4)ß(2) subtype. Derivatives 3-(((2S,4R)-4-fluoropyrrolidin-2-yl)methoxy)-5-(phenylethynyl)pyridine (11) and 3-((4-fluorophenyl)ethynyl)-5-(((2S,4R)-4-fluoropyrrolidin-2-yl)methoxy)pyridine (12) were found to be the most promising ligands identified in this study, showing good affinity and selectivity for the α(4)ß(2) subtype and physicochemical properties predictive of a relevant central nervous system penetration.
Assuntos
Flúor/química , Pirrolidinas/farmacologia , Receptores Nicotínicos/efeitos dos fármacos , Animais , Masculino , Pirrolidinas/química , Pirrolidinas/metabolismo , Ratos , Ratos Sprague-Dawley , Receptores Nicotínicos/metabolismoRESUMO
Some unichiral analogues of 2R,2'S-2-(1'-methyl-2'-pyrrolidinyl)-7-hydroxy-1,4-benzodioxane, a potent and selective α4ß2-nAChR partial agonist, were designed by opening dioxane and replacing hydroxyl carbon with nitrogen. The resulting 3-pyridyl and m-hydroxyphenyl ethers have high α4ß2 affinity and good subtype selectivity, which get lost if OH is removed from phenyl or the position of pyridine nitrogen is changed. High α4ß2 affinity and selectivity are also attained by meta hydroxylating the 3-pyridyl and the phenyl ethers of (S)-N-methylprolinol and the phenyl ether of (S)-2-azetidinemethanol, known α4ß2 agonists, although the interaction mode of the aryloxymethylene substructure cannot be assimilated to that of benzodioxane. Indeed, the α4ß2 and α3ß4 functional tests well differentiate behaviors that the binding tests homologize: both the 3-hydroxyphenyl and the 5-hydroxy-3-pyridyl ether of N-methylprolinol are α4ß2 full agonists, but only the latter is highly α4ß2/α3ß4 selective, while potent and selective partial α4ß2 agonism characterizes the hydroxybenzodioxane derivative and its two opened semirigid analogues.
Assuntos
Dioxanos/farmacologia , Agonistas Nicotínicos/síntese química , Agonistas Nicotínicos/farmacologia , Éteres Fenílicos/síntese química , Éteres Fenílicos/farmacologia , Piridinas/síntese química , Piridinas/farmacologia , Pirrolidinas/síntese química , Pirrolidinas/farmacologia , Receptores Nicotínicos/efeitos dos fármacos , Animais , Química Encefálica/efeitos dos fármacos , Linhagem Celular , Relação Dose-Resposta a Droga , Humanos , Modelos Moleculares , Conformação Molecular , Nicotina/química , Nicotina/farmacologia , Técnicas de Patch-Clamp , Ratos , Relação Estrutura-AtividadeRESUMO
New analogues (3a-l) of the previously described α4ß2 selective ligand 3-(6-halopyridin-3-yl)-3,6-diazabicyclo[3.1.1]heptanes (2a,b) have been synthesized and their binding activity for neuronal acetylcholine receptor subtypes α4ß2 and α7 were assayed. Six of these compounds (3a,b,c,j,k and l) showed high affinity and selectivity for α4ß2 receptors. The phenylpyridyl-diazabicycloheptane 3c displayed Ki value of 11.17 pM for α4ß2, in line with that of the halogenated homologues 3a,b, although it was characterized by an improved selectivity (Ki = 17 µM for α7 receptors). The influence of substitutions on the phenylpyridyl moiety on binding at both α4ß2 and α7 receptors has been examined through the Topliss decision tree analysis. Substitution with electron-donating groups (as CH3 and OCH3) resulted in a good affinity for α4ß2 receptors and substantially no affinity for α7. Amongst all the tested phenyl-substituted compounds, the p-NO2-phenyl substituted analogue 3j exhibited the highest α4ß2 affinity, with Ki value comparable to that of 3c. Intrinsic α4ß2 receptor mediated activity in [(3)H]-DA release assay was showed by compound 3a as well as by the reference analogue 2a, whereas phenyl substituted derivative 3c exhibited α4ß2 antagonist activity.
Assuntos
Compostos Azabicíclicos/metabolismo , Compostos Azabicíclicos/farmacologia , Desenho de Fármacos , Receptores Nicotínicos/metabolismo , Animais , Compostos Azabicíclicos/química , Sítios de Ligação/efeitos dos fármacos , Relação Dose-Resposta a Droga , Humanos , Estrutura Molecular , Ratos , Relação Estrutura-AtividadeRESUMO
RATIONALE: Cigarette smoking is one of the most serious health problems worldwide and people trying to stop smoking have high rates of relapse. Zebrafish (Danio rerio), by combining pharmacological and behavioral assays, is a promising animal model for rapidly screening new compounds to induce smoking cessation. OBJECTIVES: This study aims to identify possible acetylcholine nicotinic receptors (nAChRs) involved in mediating nicotine (NIC)-induced conditioned place preference (CPP) in zebrafish and investigate the effect of the CC4 and CC26 cytisine derivatives in reducing NIC-induced CPP. METHODS: CPP was evaluated using a two-compartment chamber, and the zebrafish were given CC4 (0.001-5 mg/kg), CC26 (0.001-1 mg/kg), cytisine (0.1-2.5 mg/kg), and varenicline (1-10 mg/kg) alone or with NIC (0.001 mg/kg). Swimming activity was evaluated using a square observational chamber. The affinity of the nicotinic ligands for native zebrafish brain nAChRs was evaluated by binding studies using [(3)H]-Epibatidine (Epi) and [(125)I]-αBungarotoxin (αBgtx) radioligands, and their subtype specificity was determined by means of electrophysiological assay of oocyte-expressed α4ß2 and α7 subtypes. RESULTS: CC4 and CC26 induced CPP with an inverted U-shaped dose-response curve similar to that of NIC. However, when co-administered with NIC, they blocked its reinforcing or slightly aversive effect. Binding and electrophysiological studies showed that this effect was due to binding to high-affinity heteromeric but not α7-containing receptors. CONCLUSIONS: We have further characterized CC4 and identified a new compound (CC26) that may be active in inducing smoking cessation. Zebrafish is a very useful model for screening new compounds that can affect the rewarding properties of NIC.
Assuntos
Alcaloides/farmacologia , Condicionamento Operante/efeitos dos fármacos , Nicotina/farmacologia , Agonistas Nicotínicos/farmacologia , Antagonistas Nicotínicos/farmacologia , Receptores Nicotínicos/metabolismo , Animais , Benzazepinas/farmacologia , Quinoxalinas/farmacologia , Vareniclina , Peixe-ZebraRESUMO
BACKGROUND AND PURPOSE: Many of the addictive and rewarding effects of nicotine are due to its actions on the neuronal nicotinic ACh receptor (nAChR) subtypes expressed in dopaminergic mesocorticolimbic cells. The partial agonists, cytisine and varenicline, are helpful smoking cessation aids. These drugs have a number of side effects that limit their usefulness. The aim of this study was to investigate the preclinical pharmacology of the cytisine dimer1,2-bisN-cytisinylethane (CC4). EXPERIMENTAL APPROACH: The effects of CC4 on nAChRs were investigated using in vitro assays and animal behaviours. KEY RESULTS: When electrophysiologically tested using heterologously expressed human subtypes, CC4 was less efficacious than cytisine on neuronal α4ß2, α3ß4, α7 and muscle-type receptors, and had no effect on 5-hydroxytryptamine3 receptors. Acting through α4ß2 and α6ß2 nAChRs, CC4 is a partial agonist of nAChR-mediated striatal dopamine release and, when co-incubated with nicotine, prevented nicotine's maximal effect on this response. In addition, it had low affinity for, and was less efficacious than nicotine and cytisine on the α3ß4 and α7-nAChR subtypes. Like cytisine and nicotine, CC4-induced conditioned place preference (CPP), and its self-administration shows an inverted-U dose-response curve. Pretreatment with non-reinforcing doses of CC4 significantly reduced nicotine-induced self-administration and CPP without affecting motor functions. CONCLUSION AND IMPLICATIONS: Our in vitro and in vivo findings reveal that CC4 selectively reduces behaviours associated with nicotine addiction consistent with the partial agonist selectivity of CC4 for ß2-nAChRs. The results support the possible development of CC4 or its derivatives as a promising drug for tobacco smoking cessation.